Table 4

Sugar-sweetened and artificially sweetened beverage consumption and change in serum urate levels in ARIC controls, with stratification by SLC2A9 genotype

Sweetener		Obs	Δ In serum urate, 95% CI (mmol/L)*	p Value	β_Interaction, 95% CI^†	p Value
HFCS	Unstratified	6574	0.003 (0.002 to 0.005)	6.9×10⁻⁶	0.003 (−0.000 to 0.059)	0.062
	C allele non-carrier‡	3977	0.002 (0.000 to 0.004)	0.016
	C allele carrier	2597	0.005 (0.003 to 0.007)	8.7×10⁻⁵
Artificial	Unstratified	6574	0.000 (−0.000 to 0.001)	0.48	−0.001 (−0.002 to 0.001)	0.39
	C allele non-carrier‡	3977	0.000 (−0.000 to 0.001)	0.41
	C allele carrier	2597	−0.004 (−0.013 to 0.006)	0.45

*Change per increase in consumption category (as defined for the NZ data) adjusted by age, sex, BMI, alcohol (continuous variable), fruit intake (continuous variable), kidney disease, high blood pressure and relatedness.
†Beverage consumption per day ordinal (ordered) variables (0, 1, 2, 3, 4, 5, 6) were created as described in the Supplementary Material and used as a continuous variable to derive the consumption by genotype interaction term with serum urate as outcome.
‡Genotyped with rs11942223 surrogate rs6449173 (major allele A, minor allele C)—r²=1 with rs11942223 in European Caucasian.
ARIC, Atherosclerosis Risk in Communities; NZ, New Zealand; HFCS, high fructose corn syrup; Obs, Observations.